Coronavirus (SARS-CoV-2) Cardiovascular Disease (CVD) Conditions Relationship in Diabetic and SCA Patients: a Review
Cardiovascular Disease (CVD), which is also known as Heart Disease has been the most common cause of death among diabetic and sickle cell anemia (SCA) patients around the world. CVD includes coronary artery disease, stroke, and peripheral artery disease while SCA includes hemolysis. These are the main types of CVD, which is similar to hypertension because of the common risk factors they have, such as obesity, arterial remodeling, abnormal cholesterol levels, etc. Diabetes and SCA belong to the largest health emergencies of the 21st century. With the high rate of people with diabetes and SCA, the rate of Cardiovascular Disease increases rapidly. The rates of CVD in high-income countries generally have low CVD because of the monitoring systems for non-communicable diseases like CVD. However, the appearance of the novel COVID-19/SARS-CoV-2 has changed the narrative. With COVID-19/SARS-CoV-2 attacking more on people with previous health conditions associated to cardiovascular conditions, the backbone of high-income nations is broken and those leaving with high immune conditions are at less risk whether in the high income or low-income environments. The objective of this research is to review the Cardiovascular Disease conditions to the novel COVID-19/SARS-CoV-2 in Diabetic and SCA patients. This is due to the prevalence of this medical situation in the developing world or low income and densely populated countries.
Sakamoto, Y., Nishiyama, Y., Iwasaki, Y., Daida, H., Toyoda, K., Kitagawa, K., … Shimizu, W. (2019). Design and rationale of the STroke secondary prevention with catheter ABLation and EDoxaban clinical trial in patients with non-valvular atrial fibrillation: The STABLED study. Journal of Cardiology, 74(6), 539–542. doi: 10.1016/j.jjcc.2019.06.002
Mukadas, A. O., & Misbau, U. (2009). Incidence and Patters of Cardiovascular Disease in North Western Nigeria. Nigerian Medical Journal, 50(3), 55–57.
Coccheri, S. (2007). Approaches to Prevention of Cardiovascular Complications and Events in Diabetes Mellitus. Drugs, 67(7), 997–1026. doi: 10.2165/00003495-200767070-00005
Packer, M. (2017). Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes. Diabetes Care, 41(1), 11–13. doi: 10.2337/dci17-0052
Cavan, D., Harding, J., Linnenkamp, U., Makaroff, L., Magliano, D., Ogurtsova, K., & Shaw, J. (2016). Diabetes and cardiovascular disease. International Diabetes Federation. Retrieved from https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/90:diabetes-and-cardiovascular-disease-report.html
Fornell, D. (2020). The Cardiac Implications of Novel Coronavirus. American College of Cardiology issues a clinical bulletin to update cardiologists about cardiovascular impacts of the COVID-19. Diagnostic and Interventional Cardiology. Retrieved from https://www.dicardiology.com/article/cardiac-implications-novel-coronavirus
Ferrario, C. M., Ahmad, S., & Groban, L. (2020). Mechanisms by which angiotensin-receptor blockers increase ACE2 levels. Nature Reviews Cardiology, 17(6), 378–378. doi: 10.1038/s41569-020-0387-7
Ives, J. (2020, May 4). Blood sugar control is key for people with type 2 diabetes and COVID19. Retrieved from https://www.news-medical.net/news/20200504/Blood-sugar-control-is-key-for-people-with-type-2-diabetes-and-COVID-19.aspx
Rosano, G., Vitale, C., Seferovic, P. (2017). Heart failure in patients with diabetes mellitus. Cardiac Failure Review, 3(1), 52–55.
Sanchez, E. (2020, March 24). What heart patients should know about coronavirus. Retrieved from https://www.heart.org/en/news/2020/02/27/what-heart-patients-should-know-about-coronavirus
Laguipo, A. (2020, April 28). COVID-19 could be causing potentially fatal inflammatory disease in children, doctors warn. Retrieved from https://www.news-medical.net/news/20200428/COVID-19-could-be-causing-potentially-fatal-inflammatory-disease-in-children-doctors-warn.aspx
Laguipo, A. (2020). Asymptomatic carriers transmit SARS-CoV-2 with normal breathing. Retrieved from https://www.news-medical.net/news/20200504/Asymptomatic-carriers-transmit-SARS-CoV-2-with-normal-breathing.aspx
American Heart Association. (2020). Oxygenation and Ventilation of COVID-19 Patients. Module 4: Ventilation Management. Retrieved from https://cpr.heart.org/-/media/cpr-files/resources/covid-19-resources-for-cpr-training/oxygenation-and-ventilation-of-covid-19-patients/ovcovid_mod4_vntmgmt_200401_ed.pdf
American Heart Association. (2020). Oxygenation and Ventilation of COVID-19 Patients. Module 1: Noninvasive Support Overview. Retrieved from https://www.aaup.edu/sites/default/files/OVCOVID_Mod1_Noninvasive_FIN_0.pdf
Sickle Cell Disease. Association of America (2020, May 27). Sickle cell disease and covid-19: Provider Advisory. Retrieved from https://www.sicklecelldisease.org/2020/03/18/sickle-cell-disease-and-covid-19-provider-directory
Hu, B., Ge, X., Wang, L.-F., & Shi, Z. (2015). Bat origin of human coronaviruses. Virology Journal, 12(1). doi: 10.1186/s12985-015-0422-1
Galevitz, Ph. (2020, May 8). Looking for a path to reopen, employers weigh COVID testing of workers. Retrieved from https://khn.org/news/looking-for-a-path-to-reopen-employers-weigh-covid-testing-of-workers
Mandal, A. (2020, March 29). COVID-19 and its effects on the cardiovascular system. Retrieved from https://www.news-medical.net/news/20200329/COVID-19-and-its-effects-on-the-cardiovascular-system.aspx
Thomas, L. (2020, May 5). Hydroxychloroquine shown to slow recovery for COVID-19 patients. Retrieved from https://www.news-medical.net/news/20200505/Hydroxychloroquine-shown-to-slow-recovery-for-COVID-19-patients.aspx
Thomas, L. (2020). Research detects a more dangerous SARS-CoV-2 Mutation. Retrieved from https://www.news-medical.net/news/20200504/Research-detects-a-more-dangerous-SARS-CoV-2-mutation.aspx
Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018). Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Canadian Journal of Cardiology, 34(5), 575–584. doi: 10.1016/j.cjca.2017.12.005
Shimizu, I., & Minamino, T. (2019). Cellular senescence in cardiac diseases. Journal of Cardiology, 74(4), 313–319. doi: 10.1016/j.jjcc.2019.05.002
Okura, K., Maeno, K., Okura, S., Takemori, H., Toya, D., Tanaka, N., & Miyayama, S. (2015). Pericardial fat volume is an independent risk factor for the severity of coronary artery disease in patients with preserved ejection fraction. Journal of Cardiology, 65(1), 37–41. doi: 10.1016/j.jjcc.2014.03.015
Ghani, A. C., Donnelly, C. A., Cox, D. R., Griffin, J. T., Fraser, C., Lam, T. H., … Leung, G. M. (2005). Methods for Estimating the Case Fatality Ratio for a Novel, Emerging Infectious Disease. American Journal of Epidemiology, 162(5), 479–486. doi: 10.1093/aje/kwi230
Clerkin, K. J., Fried, J. A., Raikhelkar, J., Sayer, G., Griffin, J. M., Masoumi, A., … Uriel, N. (2020). COVID-19 and Cardiovascular Disease. Circulation, 141(20), 1648–1655. doi: 10.1161/circulationaha.120.046941
Laguipo, A. (2020, May 5). Israeli scientists discover monoclonal antibody that neutralizes SARS-CoV-2. Retrieved from https://www.news-medical.net/news/20200505/Israeli-scientists-discover-monoclonal-antibody-that-neutralizes-SARS-CoV-2.aspx#:~:text=Now%2C%20in%20a%20significant%20medical,outside%20of%20a%20living%20organism
Robertson, S. (2020, May 8). Pangolins may be the key to new COVID-19 Treatments. Retrieved from https://www.news-medical.net/news/20200508/Pangolins-may-be-the-key-to-new-COVID-19-treatments.aspx
Laguipo, A. (2020, April 6). Antiparasitic drug Ivermectin kills coronavirus in 48 hours. Retrieved from https://www.news-medical.net/news/20200406/Antiparasitic-drug-Ivermectin-kills-coronavirus-in-48-hours.aspx
Thomas, T. (2020, April 27). The approved dose of ivermectin alone not useful in treating COVID-19. Retrieved from https://www.news-medical.net/news/20200427/Ivermectin-alone-not-useful-in-treating-COVID-19.aspx
Robertson, S. (2020, May 5). Cat coronavirus drug shows promise for treatment of COVID-19. Retrieved from https://www.news-medical.net/news/20200505/Cat-coronavirus-drug-shows-promise-for-treatment-of-COVID-19.aspx
Mandal, A. (2020, May 25). What happens when COVID-19 and cardiovascular diseases mix? Retrieved from https://www.news-medical.net/news/20200325/What-happens-when-COVID-19-and-cardiovascular-diseases-mix.aspx
Mourad, J.-J., & Levy, B. I. (2020). Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. Nature Reviews Cardiology, 17(5), 313–313. doi: 10.1038/s41569-020-0368-x
Kowalik, M. M., Trzonkowski, P., Łasińska-Kowara, M., Mital, A., Smiatacz, T., & Jaguszewski, M. (2020). COVID-19 — Toward a comprehensive understanding of the disease. Cardiology Journal, 27(2), 99–114. doi: 10.5603/cj.a2020.0065
Laguipo, A. (2020, April 22). Coronavirus has mutated into at least 30 Strains. Retrieved from https://www.news-medical.net/news/20200422/Coronavirus-has-mutated-into-at-least-30-strains.aspx#:~:text=Now%2C%20a%20new%20study%20reveals,different%20parts%20of%20the%20world.
Xiong, T.-Y., Redwood, S., Prendergast, B., & Chen, M. (2020). Coronaviruses and the cardiovascular system: acute and long-term implications. European Heart Journal, 41(19), 1798–1800. doi: 10.1093/eurheartj/ehaa231
Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., & Xie, X. (2020). COVID-19 and the cardiovascular system. Nature Reviews Cardiology, 17(5), 259–260. doi: 10.1038/s41569-020-0360-5
Ohm, J., Hjemdahl, P., Skoglund, P. H., Discacciati, A., Sundström, J., Hambraeus, K., … Svensson, P. (2019). Lipid levels achieved after a first myocardial infarction and the prediction of recurrent atherosclerotic cardiovascular disease. International Journal of Cardiology, 296, 1–7. doi: 10.1016/j.ijcard.2019.07.001
Sickle Cell Disease Association of America. (2020, April 1). Health Alert for People with Sickle Cell Disease and their Caregivers. Retrieved from https://www.sicklecelldisease.org/files/sites/181/2020/03/MARAC-SCDAA-Patient-Caregiver-Advisory-AFRO-VERSION.pdf
Yilgwan, C., Hyacinth, H., Ige, O., Abok, I., Yilgwan, G., John, C., … Bode-Thomas, F. (2017). Cardiovascular disease risk profile in Nigerian school children. Sahel Medical Journal, 20(4), 143. doi: 10.4103/1118-8561.230260
Hiebert, J. B., Vacek, J., Shah, Z., Rahman, F., & Pierce, J. D. (2019). Use of speckle tracking to assess heart failure with preserved ejection fraction. Journal of Cardiology, 74(5), 397–402. doi: 10.1016/j.jjcc.2019.06.004
Yakabe, D., Aso, A., Araki, M., Murasato, Y., & Nakamura, T. (2020). Efficacy of hybrid therapy using prior administration of bepridil hydrochloride and cryoballoon ablation in patients with persistent atrial fibrillation. Journal of Cardiology, 75(4), 360–367. doi: 10.1016/j.jjcc.2019.08.017
Rahman, S., Majumder, M. A. A., Kabir, R., Haque, M., Gupta, S., Arafat, S. M. Y., … Dalvi, P. (2017). Cardiovascular Disease and Diabetes: Two Sides of the Same Coin! Recent Trends in Cardiovascular Risks. doi: 10.5772/intechopen.69038National Institute of Health. (2020, April 29). NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19. Retrieved from https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19
Metrics powered by PLOS ALM
- There are currently no refbacks.
Copyright (c) 2020 Favour Deborah Adaugo Onyelowe, Kennedy Onyelowe
This work is licensed under a Creative Commons Attribution 4.0 International License.